On July 25, 2019, the Prescription Drug Pricing Reduction Act (PDPRA) of 2019 was approved by the US Senate Committee on Finance by a 19-9 vote. “The PDPRA takes a multi-pronged approach to lowering drug costs, including measures designed to improve transparency within the drug supply chain, retool the Medicare Part D program, and alter Medicare Part B drug payment methodologies.” The PDPRA will make a number of changes to drug pricing, including changes to Medicare Part B, Medicare Part D, and the Medicaid program, affecting the billing and coding procedures and calculations traditionally used for Medicaid and Medicare patients.